Search
Arrowhead Pharmaceuticals Inc
ARWRAdd to Watchlist
80.500USD
+1.610+2.04%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
11.34BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.04%
5 Days
-1.83%
1 Month
+3.32%
6 Months
+15.63%
Year to Date
+21.25%
1 Year
+400.62%
Key Figures
79.790Open
80.590High
1.66MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.18%Turnover Ratio
78.890Prev. Close
78.170Low
106.84MTurnover
LossP/E Static
18.43P/B
0.00%Div Yield TTM
-14.15%ROA
82.26052wk High
0.31Volume Ratio
-1.63MNet Profit
140.57MShares
-2.2706EPS TTM
1.29Beta
-46.39%ROE
14.30052wk Low
3.07%Amplitude
100.00%Gross Margin
11.34BMarket Cap
0.34Reward/Risk
3.72%Risk Rate
TradingKey Stock Score of Arrowhead Pharmaceuticals Inc
Currency: USD Updated: 2026-06-29Key Insights
Arrowhead Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 55 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 88.18.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Arrowhead Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Arrowhead Pharmaceuticals Inc Highlights
StrengthsRisks
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 244.55% year-on-year.
Undervalued
The company’s latest PE is -35.45, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 111.75M shares, decreasing 11.08% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.20.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
88.182
Target Price
+11.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Arrowhead Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Arrowhead Pharmaceuticals Inc Info
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Ticker SymbolARWR
CompanyArrowhead Pharmaceuticals Inc
CEOAnzalone (Christopher Richard)
Websitehttps://arrowheadpharma.com/
Related Instruments
+1.74%
+1.48%
+0.30%
+0.56%
+1.38%
+1.38%
+0.62%
+0.56%
-1.21%
+0.39%
+1.69%
+1.79%
+0.59%
+1.12%
-2.09%
0.00%
-0.17%
+2.85%
-0.74%
+0.47%Popular Instruments
FAQs
What is the current price of Arrowhead Pharmaceuticals Inc (ARWR)?
The current price of Arrowhead Pharmaceuticals Inc (ARWR) is 80.50.
What is the symbol of Arrowhead Pharmaceuticals Inc?
The ticker symbol of Arrowhead Pharmaceuticals Inc is ARWR.
What is the 52-week high of Arrowhead Pharmaceuticals Inc?
The 52-week high of Arrowhead Pharmaceuticals Inc is 82.26.
What is the 52-week low of Arrowhead Pharmaceuticals Inc?
The 52-week low of Arrowhead Pharmaceuticals Inc is 14.30.
What is the market capitalization of Arrowhead Pharmaceuticals Inc?
The market capitalization of Arrowhead Pharmaceuticals Inc is 11.32B.
Is Arrowhead Pharmaceuticals Inc (ARWR) currently rated as Buy, Hold, or Sell?
According to analysts, Arrowhead Pharmaceuticals Inc (ARWR) has an overall rating of Buy, with a price target of 88.18.
What is the Earnings Per Share (EPS TTM) of Arrowhead Pharmaceuticals Inc (ARWR)?
The Earnings Per Share (EPS TTM) of Arrowhead Pharmaceuticals Inc (ARWR) is -0.01.
